Several studies have demonstrated that TIGIT is an inhibitory receptor shared by T cells and NK cells, capable of suppressing the cytotoxic effects of NK and T cells against tumor cells, and it represents a novel target for immunotherapy [58, 59, 60, 61, 62]. Here, TIGIT is linked to neoplasm.